• Joaquim Calaf, Santiago Palacios, Ignacio Cristóbal, María Luisa Cañete, Javier Monleón, Jorge Fernández, Alicia Hernández, and Francisco Vázquez.
• Hospital de la Santa Creu i Sant Pau-Fundació Puigvert, Universitat Autònoma de Barcelona, Barcelona, España. Electronic address: JCalaf@santpau.cat.
• Med Clin (Barc). 2020 Mar 27; 154 (6): 207-213.

AimTo validate the Spanish version of the Uterine Fibroid Symptom and Quality of Life (UFS-QoL) questionnaire in women with uterine myomatosis, in order to assess severity of symptoms, and their impact on health-related quality of life.Materials And MethodsThe participants were recruited in gynaecology clinics. The UFS-QoL questionnaire comprises 37 items, 8 of which assess severity of symptoms, and the remaining 29 assess health-related quality of life in 6 subscales. Internal consistency, concurrent and discriminant validity, test-retest reliability, and the scale's sensitivity to change were evaluated.ResultsA total of 619 patients with uterine myomatosis, and 57 women without myomatosis, took part in the study. Cronbach's alpha was 0.97, and the test-retest reliability was 0.90 for the overall scale. The UFS-QoL not only discriminated between patients and healthy controls but also between patients with different degrees of uterine myomatosis. The scale responded to changes after treatment with an effect size of 1.2.ConclusionsThe Spanish version of the UFS-QoL questionnaire, used in a sample of the Spanish population, proved a valid and reliable tool to differentiate patients with uterine myomatosis and different grades of symptoms, and to evaluate the impact of the severity of these symptoms on health-related quality of life. In addition, the UFS-QoL proved sensitive to the changes generated by myomatosis treatment.Copyright © 2019 Elsevier España, S.L.U. All rights reserved.

8 keywords...

hide…